BMO Capital Downgrades Graphite Bio Inc (GRPH) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
Go back to BMO Capital Downgrades Graphite Bio Inc (GRPH) to Market Perform
January 5, 2023 5:42 PM EST
After-Hours Movers:
CytomX Therapeutics, Inc. (NASDAQ: CTMX) 52% HIGHER; The company and Moderna, Inc. (NASDAQ: MRNA) announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody therapeutic platform.
Fate Therapeutics, Inc.... More
January 5, 2023 4:05 PM EST
(Updated - January 5, 2023 4:06 PM EST)
Graphite Bio, Inc. (Nasdaq: GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious adverse event in the first patient dosed with nula-cel, and the companys conclusion that the event is likely related to study treatment. As a result, the company will not meet its guidance for initial proof-of-concept data in mid-2023.
The decision by Graphite Bio to voluntarily pause the CEDAR study follows a serious and unexpected adverse event of prolonged low blood... More
January 5, 2023 4:01 PM EST
Graphite Corp. (NASDAQ: GRPH) Halted, News Pending
...
More
